> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Treace Cuts Its Quarterly Loss 23% To $12.6 Million As Revenue Slips 4%
- URL: https://www.bullished.co/treace-cuts-its-quarterly-loss-23-to-12-6-million-as-revenue-slips-4-ad2bae0c/
- Published: 2026-11-06T12:20:38.000Z
- Updated: 2026-11-06T12:20:38.000Z
- Description: The bunion-surgery device maker narrowed its 2026 revenue range to $206 million to $210 million and now sees a smaller adjusted loss.
- Author: Matteo Parrino
- Tags: SEC Filings, TMCI, Industry: Healthcare

Treace Medical Concepts, which makes instruments, implants and surgical methods for bunion surgery, cut its third-quarter net loss 23% to [$12.6 million](https://www.sec.gov/Archives/edgar/data/0001630627/000119312526450715/tmci-ex99%5F1.htm?ref=bullished.co) even as revenue fell 4% to $48.3 million, the company said Friday. It also tightened its 2026 revenue range and lowered its expected adjusted loss.

## Cost cuts outrun a sales dip

Revenue was $48.3 million, down from $50.2 million a year earlier. The company blamed a shift toward lower-priced minimally invasive products and fewer bunion procedure kits sold. Excluding sales to stocking distributors, bunion kit volume rose and revenue grew mid-single digits.

Operating expenses fell 10% to $49.9 million from $55.4 million, which the company attributed mainly to targeted expense reductions. The net loss was $0.19 per share, against $0.26 a year earlier. Gross margin was 79.5%, from 79.1%.

Adjusted EBITDA, an earnings measure that strips out items such as stock pay, reached $0.3 million from a loss of $2.6 million. For the first nine months, that measure was still a loss of $8.7 million.

## A narrower 2026 forecast

Treace now expects 2026 revenue of $206 million to $210 million, from $204 million to $212 million, a decline of 3% to 1% from 2025\. It expects an adjusted EBITDA loss of $1.0 million to $2.0 million, from $3.0 million to $5.0 million. The company reported a $3.9 million adjusted loss for 2025.

The guidance assumes continued case volume growth and improving year-over-year revenue growth rates. Treace also reiterated that it expects cash usage to fall about 50% this year.

## Cash and the bunion business

Cash, cash equivalents and marketable securities totaled $39.8 million at September 30\. Year-to-date cash usage fell 53%, or $9.7 million, and the credit facility offers up to $115 million more in borrowing, subject to conditions.

Treace's main product is the Lapiplasty 3D Bunion Correction System, sold to surgeons. CEO John T. Treace pointed to "accelerated double-digit case volume growth" and market share gains. About 45% of Lapiplasty surgeon users now use at least one of three bunion systems launched in the third quarter of 2025, up from 40% in the second quarter of 2026.

Management held its conference call at 8:00 a.m. ET Friday to discuss the results.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — TREACE MEDICAL CONCEPTS, INC. (TMCI)](https://www.sec.gov/Archives/edgar/data/0001630627/000119312526450715/tmci-20261106.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tmci-ex99\_1.htm — TREACE MEDICAL CONCEPTS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001630627/000119312526450715/tmci-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Treace Medical Concepts Reports Third Quarter 2026](https://www.globenewswire.com/news-release/2026/11/06/3397449/0/en/treace-medical-concepts-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com